These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 20122289)

  • 1. Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy.
    Zotova E; Nicoll JA; Kalaria R; Holmes C; Boche D
    Alzheimers Res Ther; 2010 Jan; 2(1):1. PubMed ID: 20122289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's Disease is Driven by Intraneuronally Retained Beta-Amyloid Produced in the AD-Specific, βAPP-Independent Pathway: Current Perspective and Experimental Models for Tomorrow.
    Volloch V; Olsen B; Rits S
    Ann Integr Mol Med; 2020; 2(1):90-114. PubMed ID: 32617536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Precursor-Independent Overproduction of Beta-Amyloid in AD: Mitochondrial Dysfunction as Possible Initiator of Asymmetric RNA-Dependent βAPP mRNA Amplification. An Engine that Drives Alzheimer's Disease.
    Volloch V; Olsen BR; Rits S
    Ann Integr Mol Med; 2019; 1(1):61-74. PubMed ID: 31858090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antimicrobial protection hypothesis of Alzheimer's disease.
    Moir RD; Lathe R; Tanzi RE
    Alzheimers Dement; 2018 Dec; 14(12):1602-1614. PubMed ID: 30314800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral blood amyloid-β involved in the pathogenesis of Alzheimer's disease via impacting on peripheral innate immune cells.
    Shi M; Chu F; Zhu F; Zhu J
    J Neuroinflammation; 2024 Jan; 21(1):5. PubMed ID: 38178136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Examining the potential clinical value of curcumin in the prevention and diagnosis of Alzheimer's disease.
    Goozee KG; Shah TM; Sohrabi HR; Rainey-Smith SR; Brown B; Verdile G; Martins RN
    Br J Nutr; 2016 Feb; 115(3):449-65. PubMed ID: 26652155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accelerated inflammatory aging in Alzheimer's disease and its relation to amyloid, tau, and cognition.
    Cullen NC; Mälarstig AN; Stomrud E; Hansson O; Mattsson-Carlgren N
    Sci Rep; 2021 Jan; 11(1):1965. PubMed ID: 33479445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards the Integrative Theory of Alzheimer's Disease: Linking Molecular Mechanisms of Neurotoxicity, Beta-amyloid Biomarkers, and the Diagnosis.
    Molkov YI; Zaretskaia MV; Zaretsky DV
    Curr Alzheimer Res; 2023; 20(6):440-452. PubMed ID: 37605411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re-Arranging the Puzzle between the Amyloid-Beta and Tau Pathology: An APP-Centric Approach.
    Haut F; Argyrousi EK; Arancio O
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent Advances in the Modeling of Alzheimer's Disease.
    Sasaguri H; Hashimoto S; Watamura N; Sato K; Takamura R; Nagata K; Tsubuki S; Ohshima T; Yoshiki A; Sato K; Kumita W; Sasaki E; Kitazume S; Nilsson P; Winblad B; Saito T; Iwata N; Saido TC
    Front Neurosci; 2022; 16():807473. PubMed ID: 35431779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model.
    Chen XQ; Salehi A; Pearn ML; Overk C; Nguyen PD; Kleschevnikov AM; Maccecchini M; Mobley WC
    Alzheimers Dement; 2021 Feb; 17(2):271-292. PubMed ID: 32975365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease.
    Blennow K; Hampel H; Zetterberg H
    Neuropsychopharmacology; 2014 Jan; 39(1):189-201. PubMed ID: 23799530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Recent Update on Pathophysiology and Therapeutic Interventions of Alzheimer's Disease.
    Kashif M; Sivaprakasam P; Vijendra P; Waseem M; Pandurangan AK
    Curr Pharm Des; 2023; 29(43):3428-3441. PubMed ID: 38038007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tau and neuroinflammation in Alzheimer's disease: interplay mechanisms and clinical translation.
    Chen Y; Yu Y
    J Neuroinflammation; 2023 Jul; 20(1):165. PubMed ID: 37452321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amelioration of Alzheimer's disease pathology and cognitive deficits by immunomodulatory agents in animal models of Alzheimer's disease.
    Martinez B; Peplow PV
    Neural Regen Res; 2019 Jul; 14(7):1158-1176. PubMed ID: 30804241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SUMO and Alzheimer's disease.
    Lee L; Sakurai M; Matsuzaki S; Arancio O; Fraser P
    Neuromolecular Med; 2013 Dec; 15(4):720-36. PubMed ID: 23979993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
    Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid, tau, pathogen infection and antimicrobial protection in Alzheimer's disease -conformist, nonconformist, and realistic prospects for AD pathogenesis.
    Li H; Liu CC; Zheng H; Huang TY
    Transl Neurodegener; 2018; 7():34. PubMed ID: 30603085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.